Nektar Dips Into AstraZeneca's Deep Pockets With OIC Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
As Nektar reinvents itself, the specialty drug developer gets multi-million dollar validation from AstraZeneca in deal for NKTR-118.
You may also be interested in...
Gilead Gets Positive EU Opinion On Proprietary HCV Combo Pill Harvoni
Europe’s top scientific advisory panel has cleared for approval Gilead’s new hepatitis C antiviral combination of sofosbuvir plus ledipasvir, as well as Almirall’s new inhaled combo of aclidinium and formoterol and AstraZeneca’s new constipation therapy naloxegol.
AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing
Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas
AstraZeneca Pares R&D Areas By 25 Percent, But Will Continue Licensing
Following through on its R&D reduction pledge, AstraZeneca is calling off its own discovery efforts in 10 specific disease areas, though the company insists it will continue to pursue in-licensing deals in these therapeutic areas